No connection

Search Results

ABBV vs NVST

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
NVST
Envista Holdings Corporation
NEUTRAL
Price
$25.94
Market Cap
$4.23B
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
ABBV
163.63
NVST
92.64
Forward P/E
ABBV
15.42
NVST
16.64
P/B Ratio
ABBV
-146.66
NVST
1.37
P/S Ratio
ABBV
6.5
NVST
1.55
EV/EBITDA
ABBV
15.27
NVST
12.83

Profitability

Gross Margin
ABBV
71.46%
NVST
55.02%
Operating Margin
ABBV
35.5%
NVST
10.74%
Profit Margin
ABBV
4.0%
NVST
1.73%
ROE
ABBV
137.96%
NVST
1.56%
ROA
ABBV
9.59%
NVST
2.78%

Growth

Revenue Growth
ABBV
9.1%
NVST
15.0%
Earnings Growth
ABBV
-88.7%
NVST
3146.1%

Financial Health

Debt/Equity
ABBV
--
NVST
0.51
Current Ratio
ABBV
0.72
NVST
2.38
Quick Ratio
ABBV
0.47
NVST
1.93

Dividends

Dividend Yield
ABBV
3.05%
NVST
--
Payout Ratio
ABBV
490.15%
NVST
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
NVST NEUTRAL

NVST presents a complex profile with a stable Piotroski F-Score of 4/9 and a significant valuation gap, as the current price of $25.94 far exceeds the Graham Number ($10.93) and Intrinsic Value ($8.26). While the company shows strong short-term price momentum (+61.3% 1Y) and a highly attractive Forward P/E of 16.64, its trailing P/E of 92.64 and razor-thin profit margin of 1.73% indicate a precarious transition period. The bullish analyst consensus is countered by bearish insider sentiment and a 0/100 technical trend, suggesting the market is pricing in a recovery that has not yet fully materialized in the fundamentals.

Strengths
Strong liquidity with a Current Ratio of 2.38 and Quick Ratio of 1.93
Healthy Gross Margin of 55.02% indicating strong product pricing power
Manageable leverage with a Debt/Equity ratio of 0.51
Risks
Severe overvaluation relative to defensive metrics (Graham Number $10.93)
Extremely low net profit margin (1.73%) leaving little room for error
Bearish insider activity and technical trends

Compare Another Pair

ABBV vs NVST: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Envista Holdings Corporation (NVST) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile